(DNLI) – PRNewswire
-
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
-
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
-
DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING
-
Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine
-
Flagship Pioneering Debuts Enabling Technologies Initiative
-
Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders
-
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
-
Flagship Pioneering Launches Pioneering Intelligence
-
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines
-
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics
-
Flagship Pioneering Named to Fortune's 2023 "Change the World" List
-
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer
-
Invaio achieves first registration for citrus greening solution featuring Trecise™ technology
-
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner
-
Alltrna Expands Leadership Team with Appointments of Chief Scientific Officer and Chief Technology Officer
-
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines
-
Alltrna Announces Series B Raise of $109 Million to Advance tRNA Medicines for Stop Codon Disease
-
Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs
-
Alltrna Engineers tRNA Oligonucleotide with Improved Potency and Activity for In Vivo Readthrough of Premature Termination Codons
-
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
-
Senda Biosciences Announces Close of $123 Million Series C Financing
-
Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna
-
Flagship Pioneering Announces Appointment of Margo Georgiadis as CEO-Partner
-
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies for 2022
-
Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
-
INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT
-
Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology
-
Flagship Pioneering Announces Appointment of Tom DiLenge as Senior Partner, Global Public Policy, Regulatory & Governmental Strategy
-
Flagship Pioneering Announces Appointment of Justine Levin-Allerhand as Senior Partner, Corporate Development
-
Flagship Pioneering Launches Alltrna to Unlock Transfer RNA Biology and Treat Thousands of Diseases with a Single tRNA Medicine
-
Pioneering Medicines, An Initiative Of Flagship Pioneering, Establishes First-Of-Its-Kind Partnership With The Cystic Fibrosis Foundation To Develop Breakthrough Treatments For CF
-
Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
-
Laronde Attracts $440M in First External Financing to Further Advance Endless RNA™ Platform
-
Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security I
-
Flagship Pioneering Closes $3.4 Billion Capital Pool to Drive Continued Breakthrough Innovations in Human Health and Sustainability
-
Senda Biosciences Announces Closing of $98 Million Series B Financing
-
Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture
-
Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening
-
Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer
-
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
-
Flagship Pioneering Unveils Pioneering Medicines
-
Flagship Pioneering Announces Appointment of Dr. Luciano Rossetti as New Chief Medical Officer
-
Flagship Pioneering Unveils Senda Biosciences to pioneer Intersystems Biology and create novel treatments for human disease
-
Flagship Pioneering Strengthens Leadership with Appointment of Christine Heenan as Senior Partner and Chief Communications Officer
-
Flagship Pioneering Announces Appointment of Tuyen Ong as CEO-Partner
-
Flagship Pioneering Announces Valo Health to Transform Drug Development
-
Flagship Pioneering's Scientists Invent Machine Learning-Powered Platform to Generate Novel Biomedicines
-
Flagship Pioneering Expands Executive Team with Appointment of Guillaume Pfefer as CEO-Partner
-
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
-
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
Back to DNLI Stock Lookup